Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review

Background Taxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 1–3 days and lasting 5–7 days after taxane-based chemotherapy. Despite negatively impacting patient’s quality of life, little is known about the optimal TAPS management. A systematic review of treatment strategies for TAPS across all tumor sites was performed.